Spyre Therapeutics SYRE
$93.47 −$4.16 (-4.26%)
Market closed · Nov 22, 5:50 am ET · Last extended-hours $93.47 0.00%
Open$95.93
Prev close$97.63
Day range$93.22 – $99.56
Volume805.4K
Market cap$8.88B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$105.72M-85.8% YoY
Net profit-$96.12M-759.5% YoY
Diluted EPS-$0.94-526.7% YoY
Free cash flow-$77.50M-108.8% YoY
Operating cash flow-$77.50M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-42.0%
Return on assets-31.5%
Return on invested capital-47.7%
Current ratio27.40
Liabilities / assets4.4%
Cash & investments$1.07B
Net cash (debt)$1.07B
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $105.72M | $81.64M | $75.64M | $219.56M | $57.17M |
| Selling and Admin Expenses | $16.55M | $16.14M | $15.23M | $47.91M | $12.53M |
| -General & Admin Expense | $16.55M | $16.14M | $15.23M | $47.91M | $12.53M |
| Research & Development | $89.17M | $65.50M | $60.41M | $171.65M | $44.64M |
| Operating Profit | -$105.72M | -$81.64M | -$75.64M | -$219.56M | -$57.17M |
| Net Non-Operating Interest Income (Expense) | $10.63M | $10.05M | $7.00M | $24.89M | $7.14M |
| Non-Operating Interest Income | $10.63M | $10.05M | $7.00M | $24.89M | $7.14M |
| Other Income (Expense) | -$1.03M | $35.39M | -$359,000.00 | $39.46M | -$12.50M |
| Special Income (Charges) | $0.00 | $40.00M | $30.00M | $10.00M | $0.00 |
| -Gain on Sale of Property/Plant/Equipment | $0.00 | $40.00M | $30.00M | $10.00M | $0.00 |
| Other Non-Operating Income (Expenses) | -$1.03M | -$4.61M | -$30.36M | $29.46M | -$12.50M |
| Pretax Profit | -$96.12M | -$36.20M | -$69.01M | -$155.22M | -$62.53M |
| Tax | $0.00 | $0.00 | $0.00 | -$15,000.00 | $0.00 |
| Net Profit | -$96.12M | -$36.20M | -$69.01M | -$155.20M | -$62.53M |
| Profit from Continuing Operations | -$96.12M | -$36.20M | -$69.01M | -$155.20M | -$62.53M |
| Net Income to Parent Company | -$96.12M | -$36.20M | -$69.01M | -$155.20M | -$62.53M |
| Preferred Stock Dividends | -$13.01M | – | – | – | – |
| Net Income to Common Stockholders | -$83.11M | -$36.20M | -$69.01M | -$155.20M | -$80.49M |
| Basic EPS | -$0.94 | -$0.43 | -$0.74 | -$1.98 | -$0.70 |
| Diluted EPS | -$0.94 | -$0.43 | -$0.74 | -$1.98 | -$0.70 |
| Total Revenue as Reported | – | – | – | $0.00 | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.10B | $1.17B | $763.95M | $777.78M | $777.78M |
| Total Current Assets | $1.10B | $1.17B | $763.95M | $777.78M | $777.78M |
| Cash and Cash Equivalents & Short-Term Investments | $1.07B | $1.15B | $741.47M | $756.53M | $756.53M |
| -Cash and Cash Equivalents | $82.73M | $162.01M | $97.19M | $85.72M | $85.72M |
| -Short Term Investments | $989.18M | $983.34M | $644.28M | $670.81M | $670.81M |
| Other Current Assets | $27.82M | $27.66M | $22.49M | $21.25M | $21.25M |
| Total Non-Current Assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total Liabilities | $48.19M | $71.86M | $93.14M | $62.55M | $62.55M |
| Total Current Liabilities | $40.14M | $63.30M | $85.16M | $58.69M | $58.69M |
| Payables | $9.55M | $5.77M | $5.74M | $8.92M | $8.92M |
| -Accounts Payable | $9.47M | $5.72M | $5.69M | $8.90M | $8.90M |
| -Due to Related Parties Current | $82,000.00 | $46,000.00 | $50,000.00 | $14,000.00 | $14,000.00 |
| Current Accrued Expenses | $23.25M | $20.46M | $24.09M | $18.83M | $18.83M |
| Total Non-Current Liabilities | $8.05M | $8.56M | $7.98M | $3.86M | $3.86M |
| Other Non-Current Liabilities | $8.05M | $8.56M | $7.98M | $3.86M | $3.86M |
| Total Equity | $1.05B | $1.10B | $670.81M | $715.24M | $715.24M |
| Stockholders' Equity | $1.05B | $1.10B | $670.81M | $715.24M | $715.24M |
| Capital Stock | $146.44M | $146.44M | $155.84M | $155.84M | $155.84M |
| -Common Stock | $16,000.00 | $16,000.00 | $15,000.00 | $15,000.00 | $15,000.00 |
| -Preferred Stock | $146.43M | $146.43M | $155.82M | $155.82M | $155.82M |
| Additional Paid-In Capital | $2.24B | $2.19B | $1.71B | $1.69B | $1.69B |
| Retained Earnings | -$1.33B | -$1.23B | -$1.20B | -$1.13B | -$1.13B |
| Gains/Losses Not Affecting Retained Earnings | -$5.38M | -$2.40M | -$767,000.00 | $869,000.00 | $869,000.00 |
| Other Current Liabilities | – | $31.35M | $50.26M | $23.00M | $23.00M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$77.50M | -$69.88M | -$57.37M | -$169.25M | -$44.58M |
| Net cash flow from continuing operations | -$77.50M | -$69.88M | -$57.37M | -$169.25M | -$44.58M |
| Net Income from Continuing Operations | -$96.12M | -$36.20M | -$69.01M | -$155.20M | -$62.53M |
| Gain/Loss from Continuing Operations | $0.00 | -$40.00M | -$30.00M | -$10.00M | $0.00 |
| Other Non-Cash Items | $257,000.00 | $5.29M | $30.27M | -$29.77M | $12.43M |
| Change in Working Capital | $8.54M | -$9.01M | $244,000.00 | -$5.93M | -$2.27M |
| -Change in Prepaid Assets | $51,000.00 | -$5.61M | -$233,000.00 | -$12.82M | -$2.88M |
| -Change in Payables and Accrued Expense | $8.49M | -$3.40M | $477,000.00 | $6.89M | $615,000.00 |
| Net cash flow from investing | -$3.80M | -$297.90M | $56.58M | -$143.48M | -$247.41M |
| Net Cash Flow from Continuing Investing Activities | -$3.80M | -$297.90M | $56.58M | -$143.48M | -$247.41M |
| Net Intangibles Purchase and Sale | $0.00 | $40.00M | $30.00M | $7.00M | $0.00 |
| Net Investment Purchase and Sale | -$3.80M | -$337.90M | $26.58M | -$150.48M | -$247.41M |
| Financing Cash Flow | $2.02M | $432.60M | $12.26M | $309.03M | $312.81M |
| Net Cash Flow from Continuing Financing Activities | $2.02M | $432.60M | $12.26M | $309.03M | $312.81M |
| Net Common Stock Issuance | $29.53M | $435.24M | $9.75M | $311.13M | $311.13M |
| Proceeds from Stock Option Exercised | $5.59M | $20.58M | $2.68M | $3.31M | $1.75M |
| Net Other Financing Charges | -$33.10M | -$23.22M | -$171,000.00 | -$5.41M | -$69,000.00 |
| Ending Cash Balance | $82.73M | $162.01M | $97.19M | $85.72M | $85.72M |
| Net Change in Cash | -$79.28M | $64.82M | $11.46M | -$3.70M | $20.82M |
| Beginning Cash Balance | $162.01M | $97.19M | $85.72M | $89.42M | $64.90M |
| Free Cash Flow | -$77.50M | -$69.88M | -$57.37M | -$169.25M | -$44.58M |
| Depreciation & Depletion & Amortization | – | – | – | $0.00 | – |
| -Change in Receivables | – | – | – | $0.00 | – |
| -Change in Other Current Liabilities | – | – | – | $0.00 | – |
| Net PPE Purchase and Sale | – | – | – | $0.00 | – |
| Net Business Purchase and Sale | – | – | – | $0.00 | – |
| Net Preferred Stock Issuance | – | – | – | $0.00 | $0.00 |
| Effect of Exchange Rate Changes | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on SYRE.
Sign in to join the discussion.